Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 287

1.

Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells.

Chinchar E, Makey KL, Gibson J, Chen F, Cole SA, Megason GC, Vijayakumar S, Miele L, Gu JW.

Vasc Cell. 2014 Jun 1;6:12. doi: 10.1186/2045-824X-6-12. eCollection 2014.

2.

Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.

Zhang D, Sun B, Zhao X, Ma Y, Ji R, Gu Q, Dong X, Li J, Liu F, Jia X, Leng X, Zhang C, Sun R, Chi J.

Mol Cancer. 2014 Sep 8;13:207. doi: 10.1186/1476-4598-13-207.

3.

Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.

Liu H, Wang Y, Li X, Zhang YJ, Li J, Zheng YQ, Liu M, Song X, Li XR.

Tumour Biol. 2013 Jun;34(3):1713-22. doi: 10.1007/s13277-013-0708-0. Epub 2013 Feb 22.

PMID:
23430586
4.

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.

Breast Cancer Res. 2012 Apr 26;14(2):R68.

5.

Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.

Xiang L, Gilkes DM, Chaturvedi P, Luo W, Hu H, Takano N, Liang H, Semenza GL.

J Mol Med (Berl). 2014 Feb;92(2):151-64. doi: 10.1007/s00109-013-1102-5. Epub 2013 Nov 20.

6.

Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action.

Wang S, Liu Q, Zhang Y, Liu K, Yu P, Liu K, Luan J, Duan H, Lu Z, Wang F, Wu E, Yagasaki K, Zhang G.

Mol Cancer. 2009 Oct 1;8:81. doi: 10.1186/1476-4598-8-81.

7.

NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.

Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C.

Breast Cancer Res. 2011 Jun 14;13(3):R63. doi: 10.1186/bcr2900.

8.

Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.

Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM.

EMBO Mol Med. 2013 Oct;5(10):1502-22. doi: 10.1002/emmm.201302558. Epub 2013 Aug 27.

9.
10.
11.

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM.

Breast Cancer Res. 2012 May 21;14(3):R79.

12.

The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells.

Ma Y, Hao X, Zhang S, Zhang J.

Breast Cancer Res Treat. 2012 Jun;133(2):473-85. doi: 10.1007/s10549-011-1774-x. Epub 2011 Sep 23.

PMID:
21947651
13.

High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.

Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA, Allan AL.

J Cell Mol Med. 2009 Aug;13(8B):2236-52. doi: 10.1111/j.1582-4934.2008.00455.x. Epub 2008 Aug 4.

14.
15.

Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

Gründker C, Föst C, Fister S, Nolte N, Günthert AR, Emons G.

Breast Cancer Res. 2010;12(4):R49. doi: 10.1186/bcr2606. Epub 2010 Jul 14.

16.

SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.

Young E, Miele L, Tucker KB, Huang M, Wells J, Gu JW.

Cancer Biol Ther. 2010 Oct 1;10(7):703-11. doi: 10.4161/cbt.10.7.12904. Epub 2010 Oct 1.

17.

Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.

Amemiya Y, Yang W, Benatar T, Nofech-Mozes S, Yee A, Kahn H, Holloway C, Seth A.

Breast Cancer Res Treat. 2011 Apr;126(2):373-84. doi: 10.1007/s10549-010-0921-0. Epub 2010 May 13.

PMID:
20464481
18.

Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.

Zhang X, Zhang S, Liu Y, Liu J, Ma Y, Zhu Y, Zhang J.

Eur J Cancer. 2012 Jul;48(10):1581-92. doi: 10.1016/j.ejca.2012.02.053. Epub 2012 Mar 13.

PMID:
22420943
20.

ER81-shRNA inhibits growth of triple-negative human breast cancer cell line MDA-MB-231 in vivo and in vitro.

Chen Y, Zou H, Yang LY, Li Y, Wang L, Hao Y, Yang JL.

Asian Pac J Cancer Prev. 2012;13(5):2385-92.

Items per page

Supplemental Content

Write to the Help Desk